文献速递免疫规划慢病防控与筛查

23价肺炎球菌多糖疫苗通过预防心脏事件改善透析患者生存

23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events.
PubMed 文献 · Vaccine · 2019-09-13

该研究纳入8个中心2010年1038例透析患者,经1:1倾向评分匹配后510例进入分析,比较接种与未接种PPSV23组至2015年肺炎或心脏事件住院和死亡风险。结果显示接种组全因死亡显著降低(HR 0.62,95%CI 0.46-0.83,P=0.002),心脏事件住院(HR 0.44,95%CI 0.20-0.96,P=0.040)和心脏死亡(HR 0.36,95%CI 0.18-0.71,P=0.003)均显著降低,但肺炎住院和肺炎死亡无统计学差异。

要点

  • 透析患者接种PPSV23与全因死亡风险显著降低相关(HR 0.62)。
  • 接种组心脏事件住院和心脏死亡风险显著低于未接种组。
  • 肺炎住院和肺炎死亡风险两组间无统计学差异。

核心结论

  • PPSV23接种与透析患者良好预后和低心脏事件风险相关,但未显示增强的肺炎保护效力,提示可能通过直接预防心血管事件改善预后。

研究设计与样本

  • 回顾性队列研究,纳入2010年8个研究中心的1038例透析患者,采用1:1倾向评分匹配后510例进入结局分析,随访至2015年。

主要发现

  • 接种组全因死亡率显著低于未接种组(HR 0.62,95%CI 0.46-0.83,P=0.002)。
  • 接种组心脏事件住院率显著低于未接种组(HR 0.44,95%CI 0.20-0.96,P=0.040)。
  • 接种组心脏死亡 rate 显著低于未接种组(HR 0.36,95%CI 0.18-0.71,P=0.003)。
  • 肺炎住院率两组间无统计学显著差异。
  • 肺炎死亡率两组间无统计学显著差异。

临床怎么用

  • 对透析患者可考虑接种PPSV23以降低全因死亡和心脏事件风险。
  • 接种PPSV23不应替代针对肺炎的其他预防措施,因肺炎保护效力未显示增强。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunodeficient patients are recommended to receive pneumococcal vaccination. However, there is limited evidence showing effectiveness of the polysaccharide vaccine. Polysaccharide vaccination has shown an association with cardiovascular event risk reduction. We assessed the efficacy of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in relation to the risk of hospitalization and death due to pneumonia and acute cardiac events. METHODS: The medical records of all dialysis patients attending our 8 study centers in 2010 were studied, and we selected 1038 consecutive patients. One-to-one propensity score matching was used to correct for potential selection bias in a PPSV23-vaccinated group versus a non-vaccinated group, and a total of 510 patients were identified for outcome analysis. Time to first admission, or deaths due to all-cause pneumonia or cardiac events until 2015 were compared between both groups. RESULTS: The all-cause death rate was significantly decreased in the PPSV23-vaccinated group, (hazard ratio [HR] 0.62, 95% confidence interval [CI]; 0.46-0.83, P = 0.002). All-cause death was considered to be a competing risk for the other outcomes. Further outcomes were evaluated by competing risk analysis adjusting for mortality. There was no statistically significant difference in the hospitalization rate for pneumonia; however, the hospitalization rate due to cardiac events was significantly lower in the PPSV23-vaccinated group than in the non-vaccinated group (HR 0.44, 95% CI; 0.20-0.96, P = 0.040). There was no statistically significant difference in the death rate due to pneumonia; however, the rate of cardiac death was significantly lower in the PPSV23-vaccinated group than in the non-vaccinated group (HR 0.36, 95% CI; 0.18-0.71, P = 0.003). CONCLUSIONS: The PPSV23 vaccination is associated with a good prognosis and a low-risk of cardiac events in dialysis patients; however, there was no evidence indicating enhanced protective efficacy against pneumonia, suggesting the PPSV23 vaccination might improve the prognosis by directly preventing cardiovascular events.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ihara H, Kikuchi K, Taniguchi H, et al. 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events. Vaccine. 2019. PMID: 31526624. doi:10.1016/j.vaccine.2019.08.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。